Sanofi Says Its Phase 2B (STREAM-AD) Study Of Amlitelimab In Adults With Moderate-To-Severe Atopic Dermatitis Met Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Sanofi announced that its Phase 2B (STREAM-AD) study of Amlitelimab in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
June 27, 2023 | 8:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's Phase 2B study of Amlitelimab in adults with moderate-to-severe atopic dermatitis met its primary endpoint, potentially leading to a new treatment option.
The positive results from the Phase 2B study indicate that Amlitelimab has the potential to become a new treatment option for moderate-to-severe atopic dermatitis. This could lead to increased revenues for Sanofi and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100